You are viewing the site in preview mode

Skip to main content


We're creating a new version of this page. See preview

  • Invited speaker presentation
  • Open Access

S6. Proffered paper: Anti-tumour immunomodulatory activity of heat shock protein Hsp70 in therapy of malignant brain tumours: preclinical and clinical data

  • 1,
  • 2,
  • 2,
  • 3,
  • 4,
  • 1 and
  • 1
Journal for ImmunoTherapy of Cancer20142 (Suppl 2) :I3

  • Published:


  • Malignant Brain Tumour
  • Immunomodulatory Activity
  • Specific Immune Response
  • Intratumoral Injection
  • Lymphocyte Subpopulation


Immunotherapy provides a specific anti-tumour activity with minimal side effects and thus could be used in treatment of malignant brain tumours. Molecular chaperone Hsp70 is well known for its ability to stimulate innate and adaptive anti-cancer immune response. In in vivo studies we proved the efficacy of the intratumoral delivery of Hsp70 in the model of intracranial glioma C6 in animals. Based on our preclinical in vivo data we conducted for the first time pilot study for assessment of anti-tumour activity of Hsp70 in patients with brain tumours.

Material and methods

12 patients with diagnosis of malignant brain tumour were enrolled in clinical trial. Following tumour resection protein was infused into tumor cavity. Specific immune response was evaluated in delayed hypersensitivity test (DTH). Peripheral blood was monitored for possible changes in lymphocyte subpopulations cytokine levels and cytolityc activity of NK-cells. Additionally cytokine production was analyzed in dynamics in liquor after injection of Hsp70. All patients were monitored for adverse effects.


Intratumoral injections of Hsp70 were well tolerated in patients. One patient had complete clinical response and one partial response documented by radiological findings. In three patients we observed positive DTH-test. In peripheral blood we observed a shift from cytokines of those provided by Th2-helpers towards cytokines from Th1-mediated response (i.e., INF-gamma, TNF-alpha). This data corresponded to changes in lymphocyte subpopulations. NK-cell activity was not altered.


This pilot study demonstrated for the first time feasibility and safety of intratumoral delivery of recombinant Hsp70 in cancer patients. Based on our preclinical and clinical findings we proposed the novel hypothesis of immunomodulatory mechanism of Hsp70. Our results suggest that purified Hsp70 can induce specific effective anti-tumor immune response and warrants further investigation in randomised clinical trials.

Authors’ Affiliations

Institute of Cytology RAS, Saint-Petersburg, Russian Federation
A.L. Polenov Russian Scientific Research Institute of Neurosurgery, Paediatric Neurosurgery, Saint-Petersburg, Russian Federation
City Clinical Oncological Dispenser, Department of Radiology, Saint-Petersburg, Russian Federation
I.M.Sechenov Institute of Evolutionary Physiology and Biochemistry RAS, Department of Morphology, Saint-Petersburg, Russian Federation


© Shevtsov et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.